Key result
The CALM intervention significantly improved cancer-related fatigue, quality of life, and heart rate variability in patients with non-small cell lung cancer (p<0.001).
Why the study?
The study evaluated the effects of the CALM intervention on cancer-related fatigue, quality of life, and heart rate variability in non-small cell lung cancer patients.
Does the CALM intervention improve cancer-related fatigue, quality of life, and heart rate variability in NSCLC patients?
RCT (n=153)
randomly assigned
Does the CALM intervention improve cancer-related fatigue, quality of life, and heart rate variability in NSCLC patients?
The CALM intervention significantly improves cancer-related fatigue, quality of life, and autonomic function (measured by HRV) in patients with non-small cell lung cancer.
Supports CALM integration for NSCLC fatigue and QOL; extends psychosocial intervention evidence to HRV endpoints.
Objectives To evaluate the effects of CALM intervention on cancer-related fatigue (CRF), quality of life (QOL), and heart rate variability (HRV) in non-small cell lung cancer (NSCLC) patients.Methods A total of 153 NSCLC patients were enrolled in the study. Participants were randomly assigned to the CALM group and usual care (UC) group. Patients in the CALM group were received 6 CALM intervention sessions over a 12-week period and evaluated using CRF, QOL and HRV at baseline (T0) and after 2, 4, and 6 intervention sessions.Results The CALM group showed significant differences in total CRF, behavioral/daily life CRF, emotional/affective CRF, sensory/physical CRF, cognitive CRF and QOL before and after CALM intervention sessions (F = 643.47, F = 208.34, F = 354.52, F = 285.69, F = 334.29, F = 245.77, p < 0.001). The CALM group showed significant increases in standard deviation of normal R-R interval (SDNN) and high-frequency power (HF) (z = −4.94, p < 0.001,z = −4.30, p < 0.001). Significant negative correlations were observed between CRF and SDNN, HF and QOL across all participants.Conclusions The CALM intervention had a positive impact on overall physical and mental health, fatigue reduction, quality of life and autonomic dysfunction in NSCLC patients. Heart rate variability may serve as an observational indicator of physical and mental health.
No takes yet. Share an insight, caveat, or question.
Chai et al. (2024) conducted an RCT in non-small cell lung cancer (NSCLC) (n=153). CALM intervention vs. usual care (UC) was evaluated on cancer-related fatigue (CRF), quality of life (QOL), and heart rate variability (HRV) (p=<0.001). The CALM intervention significantly improved cancer-related fatigue, quality of life, and heart rate variability in patients with non-small cell lung cancer (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: